Tata Steel, Future Group, Edelweiss and ADAG stocks may hog the limelight

Here's a look at the top stocks that may remain in focus today -

IT firms, companies, markets, stocks
SI Reporter New Delhi
Last Updated : Feb 11 2019 | 9:00 AM IST
At 08:41 am, Nifty futures on the Singapore Exchange (SGX) traded 13 points or 0.12 per cent lower at 10,933.50, indicating a weak opening for the domestic stocks on Monday.  

Here's a look at the top stocks that may remain in focus today -

Results today: Over 300 companies are scheduled to release their December quarter results on Monday. Some of the prominent names include Andhra Bank, Eicher Motors, MFSL, Max India, Motherson Sumi Systems, Power Finance Corporation, Butterfly Gandhimathi Appliances, Eicher Motors, Hindustan Aeronautics (HAL), MFSL.

Tata Steel: The company reported a 54.33 per cent jump in consolidated net profit to Rs 1,753.07 crore on Friday for the quarter ended December 2018, helped by higher income.

Future Group stocks: Amazon has indefinitely put on hold its plans to buy stake in Kishore Biyani’s Future Group, said a Business Standard report.

Edelweiss, ADAG stocks: Reliance Power has asked the markets regulator Sebi to prohibit the Mumbai-based Edelweiss financial services group from trading in the securities market.

Bharti Airtel: Bharti Airtel said on Friday its unit Airtel Networks Kenya has agreed to merge with Telkom Kenya, the East African nation's smallest telecom operator.

Lupin: The drug maker on February 9 said it got two observations from US drug regulator for its Goa unit, which is under warning letter.

Apollo Hospitals: Apollo Hospitals Enterprise (AHEL) has posted 29 per cent growth in net profit to Rs 86.93 crore during the quarter ended December 31, 2018, compared to Rs 67.44 crore during the same quarter of the previous financial year.

Cochin Shipyard: State-owned Cochin Shipyard on Friday reported 14 per cent increase in net profit to Rs 129.72 crore for December quarter. The company had clocked a net profit of Rs 113.76 crore in the third quarter of 2017-18.

Dr Reddy's: The pharma company's Bachupally unit got Form 483 with 11 observations by the US Food and Drug Administration.

One subscription. Two world-class reads.

Already subscribed? Log in

Subscribe to read the full story →
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

Next Story